Company Name: Kuano
Location: Cambridge, UK
Business Focus: Drug discovery through the integration of quantum mechanics and AI
Funding Details: £1.8m
Total Funding: £2.8m.
Funding Led By: Mercia Ventures
Participation By: ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP and other angel investors.
Purpose of Funding: The funds will be used to further validate Kuano's platform, which is designed to target enzymes for potential drug creation. The company also plans to foster growth through strategic alliances and recruitment.
Background: Kuano, established in 2020 by co-founders Drs Vid Stojevic, David Wright, Parminder Ruprah, and Jarryl D’Oyley, is pioneering a novel approach to drug design. The team blends expertise from quantum physics, molecular modelling, drug discovery, and computational medicinal chemistry. Kuano's platform offers quantum simulations that grant scientists a detailed view of enzymes in their dynamic form. This insight provides a fresh avenue for devising more effective drugs. Along with the unique enzyme profiles, Kuano employs a range of AI tools to predict optimal structures to target these enzymes.
Noteworthy Achievements: The efficacy of Kuano's platform has been confirmed across three distinct disease areas, encompassing bowel cancer and lymphoma.